Toxicoproteomics -- a New Preclinical Tool
Overview
Authors
Affiliations
The publication of the human genome has presented the scientific community with an unprecedented amount of genetic information with the potential to revolutionize the drug discovery process. This information could be used to identify novel drug targets and disease markers or could aid in the development of personalized medicines. The realization that genetic changes must ultimately influence protein function has pushed the field of proteomics further into the limelight. In this review the applications of proteomics to the field of toxicology will be discussed. It is anticipated that, in the future, toxicologists will apply a range of genomic and proteomic techniques to address issues in toxicity.
Singh H, Lata S, Choudhari R, Dhole T Mol Genet Genomic Med. 2020; 8(6):e1124.
PMID: 32212330 PMC: 7284032. DOI: 10.1002/mgg3.1124.
Systems Biology to Support Nanomaterial Grouping.
Riebeling C, Jungnickel H, Luch A, Haase A Adv Exp Med Biol. 2017; 947:143-171.
PMID: 28168668 DOI: 10.1007/978-3-319-47754-1_6.
Lee Y, Choi I, Sheen Y, Park S, Kwon H Mol Cells. 2012; 33(3):309-16.
PMID: 22434383 PMC: 3887708. DOI: 10.1007/s10059-012-2280-7.
Goransson Nyberg A, Stricklin D, Sellstrom A Int J Environ Res Public Health. 2012; 8(12):4521-49.
PMID: 22408587 PMC: 3290976. DOI: 10.3390/ijerph8124521.
Moesin is a biomarker for the assessment of genotoxic carcinogens in mouse lymphoma.
Lee Y, Choi I, Sheen Y, Park S, Kwon H Mol Cells. 2012; 33(2):203-10.
PMID: 22358511 PMC: 3887720. DOI: 10.1007/s10059-012-2271-8.